Page last updated: 2024-12-05

iodohippuric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Iodohippuric acid (OIH) is an organic compound used in nuclear medicine for renal function studies. It is synthesized by reacting hippuric acid with iodine. OIH is administered intravenously and its excretion is monitored by a gamma camera. The rate of excretion is a measure of renal function, particularly glomerular filtration rate (GFR). OIH is particularly useful in assessing renal function in patients with impaired renal function due to its ability to be secreted independently of glomerular filtration. The importance of OIH lies in its ability to provide a reliable and non-invasive way to assess renal function. This is crucial for diagnosing and monitoring kidney diseases, evaluating the effectiveness of treatment, and optimizing drug dosage in patients with kidney problems. OIH is a valuable tool in clinical practice for its ability to provide insights into renal function and guide patient management.'

Iodohippuric Acid: An iodine-containing compound used in pyelography as a radiopaque medium. If labeled with radioiodine, it can be used for studies of renal function. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-iodohippuric acid : A member of the class of benzamides resulting from the formal condensation of the carboxy group of 2-iodobenzoic acid with the amino group of glycine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8614
CHEMBL ID1681
CHEBI ID140408
SCHEMBL ID589803
MeSH IDM0011662

Synonyms (55)

Synonym
147-58-0
o-iodohippuric acid
NCGC00160456-01
NCGC00160456-02
2-iodohippuric acid, 98%
NCIOPEN2_008020
inchi=1/c9h8ino3/c10-7-4-2-1-3-6(7)9(14)11-5-8(12)13/h1-4h,5h2,(h,11,14)(h,12,13
o-iodobenzoylglycine
iodohippurate
iodohippuric acid
2-(2-iodobenzamido)acetic acid
CHEBI:140408
ortho-iodohippuric acid
ortho-iodobenzoylglycine
n-(o-iodobenzoyl)glycine
2-[(2-iodobenzoyl)amino]acetic acid
n-(2-iodobenzoyl)glycine
I0446
2-iodohippuric acid
CHEMBL1681
AKOS000120821
dtxsid8046161 ,
tox21_111826
dtxcid6026161
cas-147-58-0
glycine,n-(2-iodobenzoyl)-
MLS004773944
smr002529473
3y68k91a3m ,
einecs 205-693-5
unii-3y68k91a3m
glycine, n-(2-iodobenzoyl)-
iodohippurate [vandf]
o-iodohippuric acid [usp-rs]
iodohippuric acid [who-dd]
SCHEMBL589803
2-[(2-iodophenyl)formamido]acetic acid
NCGC00160456-03
tox21_111826_1
[(2-iodobenzoyl)amino]acetic acid #
2'-iodohippuric acid
mfcd00002694
o-iodohippuric acid, united states pharmacopeia (usp) reference standard
J-008368
FT-0762272
CS-0201684
DB15445
Q25323818
2-(2-iodobenzamido)aceticacid
STR01314
2-iodohippuric-acid
D91155
HY-W141890
EN300-18563
Z85887266

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Safety and tolerability were assessed until disease progression or an intolerable adverse event (AE)."( Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.
Bono, P; Fizazi, K; Lietuvietis, V; Massard, C; Nykänen, P; Penttinen, HM; Pohjanjousi, P; Snapir, A; Tammela, TL; Vjaters, E; Vuorela, A, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" Problems associated with the use of an oversimplified pharmacokinetic model for clearance calculations are discussed, together with the concept of model-independent calculations."( Error dependent on renal function when monoexponential equation assumed. Serum clearances of 125I-iothalamate and 131I-o-iodohippurate.
Dobrinska, MR; MacKichan, JJ; Wagner, JG; Welling, PG, 1977
)
0.26
" For interpretation of clinical findings, extensive pharmacokinetic studies were performed on patients."( Pharmacokinetics of technetium-99m-MAG3 in humans.
Brandau, W; Bubeck, B; Georgi, P; Kälble, T; Parekh, N; Weber, E, 1990
)
0.28
"We applied an open one compartment pharmacokinetic model for the determination of glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) based on a rapid intravenous loading dose followed by a constant infusion of 125I-iothalamate and 131I-orthoiodohippurate in order to ensure constant plasma levels of the two clearance markers."( Optimising glomerular filtration rate and effective renal plasma flow measurements using a simple pharmacokinetic model.
Balk, AH; Blankestijn, PJ; Derkx, FH; Pos, B; Schalekamp, MA; Weimar, W; Zietse, R, 1995
)
0.29
" Using obtained time-concentration data, classical 2 compartment model analysis was performed for both tracers to obtain various pharmacokinetic parameters, including distribution volumes (Vds), inter-compartmental rate constants, and plasma clearance."( [Pharmacokinetics of 99mTc-MAG3 and 131I-OIH: comparative study based on 2 compartment model analysis].
Aburano, T; Ishikawa, Y; Kaneko, S; Kikuchi, K; Kubo, Y; Mizunaga, M; Ogawa, Y; Saito, Y; Sasajima, T; Sato, J; Shuke, N; Takashio, T; Yachiku, S; Yamamoto, W, 1996
)
0.29
"Na(2)[(99m)Tc(CO)(3)(NTA)] is stable, exists as a single species, and has pharmacodynamic properties in rats comparable to those of (131)I-OIH."( 99mTc(CO)3-nitrilotriacetic acid: a new renal radiopharmaceutical showing pharmacokinetic properties in rats comparable to those of 131I-OIH.
Lipowska, M; Marzilli, LG; Taylor, AT, 2009
)
0.35
"Preliminary results in healthy volunteers suggest that the pharmacokinetic behavior of (99m)Tc(CO)(3)(NTA) is comparable to that of (131)I-OIH."( (99m)Tc(CO)3(NTA): a (99m)Tc renal tracer with pharmacokinetic properties comparable to those of (131)I-OIH in healthy volunteers.
Lipowska, M; Marzilli, LG; Taylor, AT, 2010
)
0.36
"In an ongoing effort to develop a renal tracer with pharmacokinetic properties comparable to p-aminohippurate and superior to those of both (99m)Tc-mercaptoacetyltriglycine and (131)I-o-iodohippurate ((131)I-OIH), we evaluated a new renal tricarbonyl radiotracer based on the aspartic-N-monoacetic acid (ASMA) ligand, (99m)Tc(CO)(3)(ASMA)."( Preclinical evaluation of 99mTc(CO)3-aspartic-N-monoacetic acid, a renal radiotracer with pharmacokinetic properties comparable to 131I-o-iodohippurate.
Klenc, J; Lipowska, M; Marzilli, LG; Taylor, AT, 2012
)
0.38
"Both (99m)Tc(CO)(3)(ASMA) complexes have pharmacokinetic properties in rats comparable to or superior to those of (131)I-OIH, and human studies are warranted for their further evaluation."( Preclinical evaluation of 99mTc(CO)3-aspartic-N-monoacetic acid, a renal radiotracer with pharmacokinetic properties comparable to 131I-o-iodohippurate.
Klenc, J; Lipowska, M; Marzilli, LG; Taylor, AT, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" Some animals received 200 mg/kg probenecid intraperitoneally and this reduced the rate of absorption from injectates into the corpus striatum to 65."( Organic acid transport to the blood from the corpus striatum, the thalamus and the cerebellum of the rat.
Andén, NE; Bárány, E; Grabowska-Andén, M; Magnusson, A, 1984
)
0.27
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Comparison of these studies indicates that most periodic re-evaluations with IVP can be eliminated in favor of the scintillation study with its markedly reduced radiation dosage and lack of allergic type reactions."( 131I hippuran quantitative scintillation camera studies in the evaluation and management of vesicoureteral reflux.
Bueschen, AJ; Colfry, AJ; Evans, BB; Schelegal, JU, 1975
)
0.25
" This study was designed to determine the dose-response effects of CGRP infusion in the intact conscious sheep on blood flow to liver and kidney, organs known to be richly innervated by CGRP-containing nerves."( Calcitonin gene related peptide: vasodilator in ovine hepatic and renal vasculature.
Braslis, KG; Fletcher, DR; Hardy, KJ; Shulkes, A, 1990
)
0.28
" For this reason the authors have adopted a diagnostic protocol, which is based on the association of the urinary excretion dosage of beta 2 microglobulin, with sequential renal scan with Hippuran 123."( [Determination of the urinary secretion of beta 2-microglobulin combined with sequential renal scintigraphy using H123 for the early diagnosis of pyelonephritis in children].
Coletta, A; Coletta, S; Di Pietro, A; La Penta, L; Pescatore, L; Proverbio, MR; Race, G,
)
0.13
" H2O the excretion of isotope from the contralateral kidney varied from two to 26% of the dosage given."( 125I-hippuran absorption from the human renal pelvis.
Bratt, CG; Granerus, G, 1986
)
0.27
" Lowering the dosage of CyA permitted the continuation of therapy, and all 9 patients are alive after 8 to 14 months."( 99mTc-DTPA and 131I-hippuran findings in liver transplant recipients treated with cyclosporin A.
Iwatsuki, S; Klingensmith, WC; Klintmalm, GB; Schröter, GP; Starzl, TE, 1982
)
0.26
" Meticulous attention to proper patient preparation, radiopharmaceutical selection, furosemide dosage and administration, and image interpretation and an awareness of potential pitfalls are essential for accurate diagnosis."( Provocative imaging. Diuretic renography.
Roarke, MC; Sandler, CM, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
N-acylglycineAn N-acyl-amino acid in which amino acid specified is glycine.
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency36.12540.007215.758889.3584AID624030
RAR-related orphan receptor gammaMus musculus (house mouse)Potency2.37100.006038.004119,952.5996AID1159521
farnesoid X nuclear receptorHomo sapiens (human)Potency0.07500.375827.485161.6524AID743220
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.08490.023723.228263.5986AID743223
lamin isoform A-delta10Homo sapiens (human)Potency8.91250.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID388273Ratio of Vm(app) to Km(app) for rat recombinant peptidylglycine alpha-amidating monooxygenase2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID388272Activity of rat recombinant peptidylglycine alpha-amidating monooxygenase assessed as stimulation of oxygen consumption2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID388274Ratio of Vm(app) to Km(app) for rat recombinant peptidylglycine alpha-amidating monooxygenase relative to hippuric acid2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,852)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901601 (86.45)18.7374
1990's189 (10.21)18.2507
2000's35 (1.89)29.6817
2010's18 (0.97)24.3611
2020's9 (0.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 6.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index6.54 (24.57)
Research Supply Index7.61 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (6.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials35 (1.77%)5.53%
Reviews51 (2.57%)6.00%
Case Studies88 (4.44%)4.05%
Observational0 (0.00%)0.25%
Other1,808 (91.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]